Company Filing History:
Years Active: 2014-2015
Title: Fabien Delacote: Innovator in Genome Engineering
Introduction
Fabien Delacote is a prominent inventor based in Paris, France. He has made significant contributions to the field of genome engineering, particularly through his innovative methods for modulating double-strand break-induced mutagenesis and homologous recombination. With a total of 2 patents, Delacote's work is paving the way for advancements in therapeutic applications and cell line engineering.
Latest Patents
Delacote's latest patents include a method for modulating the efficiency of double-strand break-induced mutagenesis. This method provides new tools for genome engineering by allowing for the modulation of double-strand break-induced mutagenesis at a genomic locus of interest in a cell. It involves the identification of effectors that can influence this process through interfering agents. These agents can enhance double-strand break-induced mutagenesis, offering potential applications in therapeutic settings.
Another significant patent by Delacote focuses on modulating double-strand break-induced homologous recombination. This invention identifies effectors that can enhance homologous recombination through the use of interfering agents. By introducing these agents into eukaryotic cells, the efficiency of gene targeting can be improved, which is crucial for various genetic engineering applications.
Career Highlights
Throughout his career, Fabien Delacote has worked with notable companies such as Cellectis and Cellectis S.A. His experience in these organizations has contributed to his expertise in genome engineering and patent development.
Collaborations
Delacote has collaborated with esteemed colleagues, including Philippe Duchateau and Christophe Perez-Michaut. These partnerships have further enriched his research and innovation in the field.
Conclusion
Fabien Delacote's contributions to genome engineering through his innovative patents are noteworthy. His work not only enhances our understanding of genetic manipulation but also opens new avenues for therapeutic applications.